Tyrosine kinase inhibitor

Phase 3Small molecule

Tyrosine kinase inhibitor is one of 50 small molecule programs targeting Metastatic Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Hepatocellular CarcinomaRecruiting

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveActive, not recruiting

Phase IIRecruiting

Acute Leukemia of Ambiguous LineageRecruiting

Metastatic Hepatocellular CarcinomaPhase 2

Recruiting

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositivePhase 2

Active, not recruiting

Phase IIPhase 3

Recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Recruiting

Competition

Competitive Landscape

33 competitors in Phase II

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Rituxan

Roche

Phase 2

4 3

Lynparza

AstraZeneca

Phase 2

2 4

LUNSUMIO

Roche

Phase 2

1 5

Polivy

Roche

Phase 2

1 6

Herceptin

Roche

Phase 2

1 7

Imfinzi

AstraZeneca

Phase 2

1 8

Adriamycin

Pfizer

Phase 2

1 9

SKB264

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

1 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Phase II

NCT05236946

Q4 2027

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT04440267

Q2 2028

Recruiting

Non-Small Cell Lung Cancer

NCT03958565

Q3 2031

Phase 2Recruiting

Metastatic Hepatocellular Carcinoma

NCT07219459

Clinical

Trials by Indication[1]

Myeloid Leukemia3 trials

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Terminated·MMilton S. Hershey Medical Center·Phase 1/2·NCT04006847·1 enrolled

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01460498·3 enrolled

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Terminated·EEmory University·Phase 2·NCT02730195·9 enrolled

Non-Small Cell Lung Cancer2 trials

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting·UUniversity of Colorado, Denver··NCT03958565·100 enrolled

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Terminated·WWake Forest University Health Sciences·Phase 2·NCT02949843·19 enrolled

Phase II1 trial

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Recruiting·TTata Memorial Hospital·Phase 3·NCT05236946·190 enrolled

Lung Cancer1 trial

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Unknown status·—·Phase 1/2·NCT03799094·150 enrolled

Ph+ ALL1 trial

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03624530·82 enrolled

7 more indications

Completed· Pfizer logo

Pfizer··NCT04375150·355 enrolled

Immune Checkpoint Inhibitors1 trial

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, not recruiting·FFirst Hospital of China Medical University··NCT06632106·97 enrolled

Metastatic Hepatocellular Carcinoma1 trial

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT03817398·110 enrolled

NSCLC1 trial

Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04318938·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Tyrosine kinase inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tyrosine kinase inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tyrosine kinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Tyrosine kinase inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q3 2031

Trials by Indication[1]

Myeloid Leukemia3 trials

Non-Small Cell Lung Cancer2 trials

Phase II1 trial

Lung Cancer1 trial

Ph+ ALL1 trial

Breast Cancer1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Medication Adherence1 trial

Immune Checkpoint Inhibitors1 trial

Metastatic Hepatocellular Carcinoma1 trial

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News